Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AbCellera Biologics (ABCL)
NASDAQ:ABCL
AbCellera Biologics (ABCL) Stock Price & Analysis
1,318 Followers
ABCL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.87 - $8.05
Previous Close$3.92
Volume765.65K
Average Volume (3M)1.36M
Market Cap
$1.15B
Enterprise Value$471.61M
Total Cash (Recent Filing)$760.59M
Total Debt (Recent Filing)$84.49M
Price to Earnings (P/E)-7.7
Beta1.09
Next Earnings
May 07, 2024EPS Estimate
-$0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding289,355,867
10 Day Avg. Volume1,053,736
30 Day Avg. Volume1,361,263
Standard Deviation0.18
R-Squared0.01
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)1.19
Price to Sales (P/S)91.76
Price to Cash Flow (P/CF)-14.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue24.84
Enterprise Value/Gross Profit10.53
Enterprise Value/Ebitda-6.60
Forecast
1Y Price Target
$13.60Price Target Upside247.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
AbCellera Biologics News
PremiumCompany Announcements
Peter Thiel Retires from AbCellera Board, Dr. Andrew Lo Steps In
Bulls Say, Bears Say
Bulls Say
Financial HealthAbCellera's strong financial position, with over $1 billion in liquidity, positions the company to effectively invest in its innovative programs and strengthen its operational capabilities.
Pipeline DevelopmentAbCellera's internal pipeline, especially with T-cell engagers, is anticipated to attract major Pharma interest, potentially leading to lucrative licensing deals and bolstering the stock.
Strategic PartnershipsAnalyst expects a strategic partnership deal to materialize, leveraging AbCellera's extensive TCE assets and their potential in cancer treatment, which could significantly enhance shareholder value.
Bears Say
Company RestructuringABCL disclosed a 10% workforce reduction to focus resources on clinical development of its internal and partner programs.
Operational EfficiencyThe company's downsizing move, while optimizing resources for clinical development, indicates potential challenges in sustaining its previous operational scope.
Research And DevelopmentManagement continues to see value in AI drug development, but key breakthroughs likely remain further away.
---
Ownership Overview
47.64% Insiders
4.50% Mutual Funds
1.32% Other Institutional Investors
46.54% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABCL FAQ
What was AbCellera Biologics’s price range in the past 12 months?
AbCellera Biologics lowest stock price was $3.87 and its highest was $8.05 in the past 12 months.
What is AbCellera Biologics’s market cap?
Currently, no data Available
When is AbCellera Biologics’s upcoming earnings report date?
AbCellera Biologics’s upcoming earnings report date is May 07, 2024 which is in 18 days.
How were AbCellera Biologics’s earnings last quarter?
AbCellera Biologics released its earnings results on Feb 20, 2024. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.115 by -$0.045.
Is AbCellera Biologics overvalued?
According to Wall Street analysts AbCellera Biologics’s price is currently Undervalued.
Does AbCellera Biologics pay dividends?
AbCellera Biologics does not currently pay dividends.
What is AbCellera Biologics’s EPS estimate?
AbCellera Biologics’s EPS estimate is -$0.13.
How many shares outstanding does AbCellera Biologics have?
AbCellera Biologics has 292,782,170 shares outstanding.
What happened to AbCellera Biologics’s price movement after its last earnings report?
AbCellera Biologics reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.115. Following the earnings report the stock price went down -9.416%.
Which hedge fund is a major shareholder of AbCellera Biologics?
Among the largest hedge funds holding AbCellera Biologics’s share is Baker Bros Advisors LP. It holds AbCellera Biologics’s shares valued at 131M.
---
AbCellera Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.60 (247.83% Upside)
$13.60 (247.83% Upside)
Blogger Sentiment
Bullish
ABCL Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $151.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.95%
12-Months-Change
Fundamentals
Return on Equity
-12.27%
Trailing 12-Months
Asset Growth
-3.43%
Trailing 12-Months
Company Description
AbCellera Biologics
AbCellera Biologics Inc is a biotechnology company. The company develops antibodies to treat highly infectious diseases and various other types of diseases.
---
ABCL Company Deck
---
ABCL Earnings Call
Q4 2024
0:00 / 0:00
---
ABCL Revenue Breakdown
93.51% Research fees
3.94% Royalty revenue
2.55% Milestone payments
---
ABCL Stock 12 Months Forecast
Average Price Target
$13.60
▲(247.83% Upside)
Technical Analysis
Best Analysts Covering ABCL
1 Year
1 Year Success Rate
1/9 ratings generated profit
1 Year Average Return
-39.74%
reiterated a buy rating 2 months ago
Copying Stephen Willey's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -39.74% per trade.
---